- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07568847
Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder (HOTPIN-IF)
Facilitating In-Hospital Opioid Treatment Program Intakes to Support Hospital to OTP Linkage Among Hospitalized Patients With Opioid Use Disorder: An Implementation Trial in Four Hospitals
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of this study is to test whether a hospital-based approach can improve connection to methadone treatment after discharge. The approach includes completing OTP intake during hospitalization and supporting hospital teams through an implementation strategy called implementation facilitation (IF). This study also aims to understand how well the approach can be adopted and sustained across different hospitals. This is a multi-site clinical trial conducted at four hospitals. The study uses a hybrid type 2 implementation-effectiveness design, meaning it evaluates both patient outcomes and how the intervention is implemented. The study uses an incomplete stepped wedge cluster randomized design. In this design:
- All hospitals begin in a usual care phase
- Hospitals are randomly assigned a time to switch to the intervention
- Over time, each hospital transitions from usual care to the intervention phase
- This allows each hospital to serve as its own comparison
During the usual care phase, patients receive standard care, which includes referral to an OTP at discharge. During the intervention phase, hospital teams receive implementation support to help complete OTP intake during the hospital stay. The intervention is an implementation strategy designed to support hospital teams in completing OTP intake during hospitalization.
The study uses the RE-AIM framework to evaluate outcomes:
- Reach: The number and characteristics of patients who complete OTP intake and connect to care.
- Effectiveness: The primary outcome is connection to an OTP after hospital discharge (for example, within 7 days). Secondary outcomes may include engagement in treatment at 30 and 90 days, healthcare use, and mortality.
- Adoption: The proportion of hospital clinicians and teams who use the new workflows and complete OTP intake.
- Implementation: How well the intervention is delivered, including fidelity to core components, adaptations, and resources used.
- Maintenance: Whether the intervention is sustained over time after initial implementation.
The study will also assess implementation costs and identify barriers and facilitators to adoption.
Participants are adults with OUD who are hospitalized and interested in starting methadone treatment. Participants must be willing to connect to a methadone clinic after discharge.
Data will be collected from multiple sources, including:
- Electronic health records (EHRs) from participating hospitals
- Data from opioid treatment programs (when available)
- Study questionnaires completed during enrollment
- Administrative data on healthcare use
- National Death Index data for mortality outcomes
- Data will be combined across sites using a structured data approach to ensure consistency.
The analysis will evaluate:
- Differences in OTP connection rates
- Changes in treatment engagement over time
- Variation across hospitals
- Implementation outcomes and costs
- Qualitative data from interviews and observations may also be used to understand how the intervention works in real-world settings.
This study addresses a major gap in care for people with OUD. Improving connection to methadone treatment after hospitalization has the potential to reduce overdose deaths, improve health outcomes, and reduce healthcare use. By testing both effectiveness and implementation, this study will provide practical information for scaling this approach across hospitals.
If successful, this model could be widely adopted to improve access to life-saving treatment for people with OUD.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Susan L Calcaterra, MD, MPH, MS
- Telefonnummer: 2487035947
- E-post: susan.calcaterra@cuanschutz.edu
Studer Kontakt Backup
- Navn: Sarah Mann, MA
- E-post: sarah.mann@cuanschutz.edu
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Hospitalized with DSM-5 opioid use disorder, confirmed by clinical assessment
- Eligible for methadone treatment as determined by the clinical team
- Not currently enrolled in an Opioid Treatment Program (OTP)
- Anticipated discharge to the community
- Willing to initiate methadone and follow up at a partnering OTP
Exclusion Criteria:
- Current enrollment in an Opioid Treatment Program (OTP)
- Planned discharge to a correctional or institutional setting that precludes OTP follow-up
- Medical or psychiatric instability that precludes safe methadone initiation or completion of study procedures
- Inability to provide required information for OTP intake due to impaired cognition or altered mental status
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: N/A
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Usual Care
Standard hospital-to-OTP referral processes without implementation facilitation
|
Participants receive care at sites after rollout of Implementation Facilitation (IF) to support HOTPIN workflows. Focus on completing in-hospital OTP intake, including: Medical assessment Screening labs Methadone initiation Transportation coordination Supported by: External facilitators Learning collaboratives Workflow integration into the EHR |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
7-Day Hospital-to-OTP Linkage
Tidsramme: Measured within 7 days following hospital discharge
|
The primary outcome is whether a participant successfully connects to an Opioid Treatment Program (OTP) within 7 days after hospital discharge. Connection" (linkage) is defined as: Completion of OTP intake and/or attendance at the OTP, and Receipt or continuation of methadone treatment at the OTP |
Measured within 7 days following hospital discharge
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
30-Day OTP Engagement
Tidsramme: 30 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an Opioid Treatment Program (OTP) within 30 days after hospital discharge. Defined by ongoing dosing or documented attendance at the OTP Reflects short-term treatment retention |
30 days after hospital discharge
|
|
90-Day OTP Engagement (Retention)
Tidsramme: Within 90 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an OTP within 90 days after hospital discharge. Defined by continued dosing records or clinic attendance Reflects longer-term treatment retention |
Within 90 days after hospital discharge
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Healthcare Utilization After Discharge
Tidsramme: 90 days following hospital discharge
|
Description: Rates of emergency department visits and hospital readmissions following the index hospitalization. Assessed using hospital administrative and EHR data |
90 days following hospital discharge
|
|
All-cause mortality following hospital discharge.
Tidsramme: 90 days after hospital disharge
|
Assessed using linkage to the National Death Index (NDI)
|
90 days after hospital disharge
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Susan L Calcaterra, MD, MPH, MS, University of Colorado, Denver
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 26-0455
- 1R01DA063733-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
We will share de-identified individual participant data (IPD) using a controlled access process (not open download)
We will require:
Data Use Agreement (DUA) IRB approval or exemption data security plan
We will exclude:
Direct identifiers Anything restricted under 42 CFR Part 2 without proper authorization
IPD-delingstidsramme
Time Frame:
Data will be available beginning 12 months after publication of the primary results and ending 5 years after publication.
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .